Marjolaine Gauthier-Loiselle
 
                    Education
Ph.D., economics, Princeton University; M.S., economics, and B.S., economics and mathematics, Université de Montréal
Summary of Experience
Dr. Gauthier-Loiselle specializes in health economics and outcomes research (HEOR). She has conducted research on several diseases and in therapeutic areas such as neuropsychiatry, oncology, nephrology, endocrinology, cardiology, infectious diseases, and rare and hereditary diseases. Dr. Gauthier-Loiselle has extensive experience conducting quantitative research using data from a variety of sources, including health insurance claims, electronic medical records, large national surveys, and clinical trials. Her work includes patient and physician surveys, chart review studies, economic burden studies, treatment pattern studies, safety profile studies, and predictive risk modeling. Dr. Gauthier-Loiselle has served as a peer reviewer for a number of publications, and has published research in several peer-reviewed journals such as the Journal of the American Academy of Dermatology, the Journal of Alzheimer’s Disease, and Cardiovascular Diabetology. Her research has been presented at numerous international clinical conferences. Dr. Gauthier-Loiselle is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
- 
                                                        A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementiaJournal of Medical Economics, 2024 
 2024Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guerin A, Aggarwal J 
- 
                                                        Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)PharmacoEconomics, 2024 
 2024DuBrock HM, Germack HD, Gauthier-Loiselle M, Linder J, Satija A, Manceur AM, Cloutier M, Lefebvre P, Panjabi S, Frantz RP 
- 
                                                        Impact of Invasive Escherichia coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United StatesInfectious Diseases and Therapy, 2024 
 2024Zhuo C, Zheng B, Wattanakamolkul K, Nakayama Y, Cloutier M, Gauthier-Loiselle M, Feng J, Wu D, Neary MP, Geurtsen J, El Khoury AC, Gu Y 
- 
                                                        Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorderJournal of Medical Economics, 2024 
 2024Schein J, Cloutier M, Bungay R, Gauthier-Loiselle M, Childress A 
- 
                                                        Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experimentJournal of Dermatological Treatment, 2024 
 2024Feldman SR, Guérin A, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, Gallant K, Balu S 
- 
                                                        Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder: a claims-based case-cohort studyChild and Adolescent Psychiatry and Mental Health, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Guerin A, Childress A 
- 
                                                        Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorderJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Childress A 
- 
                                                        Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta)Current Medical Research and Opinion, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Childress A 
- 
                                                        Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-releaseJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Chan D, Childress A 
- 
                                                        Treatment Preferences of Adult Patients with Attention-Deficit/Hyperactivity Disorder - A Discrete Choice ExperimentPatient Preference and Adherence, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Meng Y, Libchaber B, Jiang F, Childress A 
- 
                                                        A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacyJournal of Comparative Effectiveness Research, 2024 
 2024Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Lee F, Childress A 
- 
                                                        Economic Burden of Illness among Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disorders (CTD)Pulmonary Circulation, 2023 
 2023Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Liu S, Cloutier M, Lefebvre P 
- 
                                                        Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control studyBMC Psychiatry, 2023 
 2023Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Arpin E, Guerin A, Childress A 
- 
                                                        Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United StatesBMC Infectious Diseases, 2023 
 2023Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Gauthier-Loiselle M, Bungay R, Cloutier M, Sarnecki M, Saade E 
- 
                                                        Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United StatesJournal of Managed Care & Specialty Pharmacy, 2023 
 2023Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Krishnarajah G, Gauthier-Loiselle M, Bungay R, Cloutier M, Saade E 
- 
                                                        Enhancement and external validation of algorithms using diagnosis codes to identify invasive Escherichia Coli diseaseCurrent Medical Research and Opinion, 2023 
 2023Hernandez-Pastor L, Geurtsen J, El Khoury AC, Fortin SP, Gauthier-Loiselle M, Yu LH, Cloutier M 
- 
                                                        Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based AnalysisAdvances in Therapy, 2023 
 2023Sargent T, Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, Cloutier M, Lefebvre P 
- 
                                                        Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHDCurrent Medical Research and Opinion, 2022 
 2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A 
- 
                                                        Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based SurveyKidney Medicine, 2022 
 2022Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB 
- 
                                                        Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims dataCurrent Medical Research and Opinion, 2022 
 2022Gauthier-Loiselle M, Tsang Y, Lefebvre P, Agron P, Royer J, Lynum KB, Bennett L, Panjabi S 
- 
                                                        Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review StudyAdvances in Therapy, 2022 
 2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A 
- 
                                                        Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United StatesCurrent Medical Research and Opinion, 2021 
 2021Willey C, Gauthier-Loiselle M, Cloutier M, Shi S, Maitland J, Stellhorn R, Sanon Aigbogun M 
- 
                                                        Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional StudyNephrology Nursing Journal, 2021 
 2021Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T 
- 
                                                        Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspectiveJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A 
- 
                                                        Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolismCurrent Medical Research and Opinion, 2021 
 2021Kanwar MK, Cole M, Gauthier-Loiselle M, Manceur AM, Tsang Y, Lefebvre P, Panjabi S, Benza RL 
- 
                                                        Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisAdvances in Therapy, 2021 
 2021Gauthier-Loiselle M, Cloutier M, Toro W, Patel A, Shi S, Davidson M, Bischof M, LaMarca N, Dabbous O 
- 
                                                        The societal economic burden of autosomal dominant polycystic kidney disease in the United StatesBMC Health Services Research 
 2020Cloutier M, Manceur AM, Guerin A, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M 
- 
                                                        Economic burden of spinal muscular atrophy in the United States: a contemporary assessmentJournal of Medical Economics, 2020 
 2020Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O 
- 
                                                        Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart ReviewJournal of Alzheimer's Disease, 2020 
 2020Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H 
- 
                                                        Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational studyCurrent Medical Research and Opinion, 2019 
 2019Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB 
- 
                                                        The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey AnalysisJournal of Managed Care & Specialty Pharmacy, 2019 
 2019Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ 
- 
                                                        Institutionalization risk and costs associated with agitation in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019 
 2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS 
- 
                                                        Claims-Based Risk Model for First Severe COPD ExacerbationAmerican Journal of Managed Care. February 2018;24(2):e45-e53. 
 2018Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP, Duh MS 
- 
                                                        Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based AnalysisJ Drugs Dermatol. Feb 1 2018;17(2):180-186 
 2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A 
- 
                                                        Assessment of costs associated with adverse events in patients with cancerPloS One. 2018;13(4):e0196007 
 2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A 
- 
                                                        Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based AnalysisJ Drugs Dermatol. Feb 1 2018;17(2):187-194 
 2018Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A 
- 
                                                        The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort studyJournal of the American Academy of Dermatology. 2018 Jul;79(1):60-68 
 2018Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A 
- 
                                                        Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims dataCardiovascular Diabetology. Aug 24 2018;17(1):118 
 2018Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH 
- 
                                                        Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology settingUrologic Oncology. 2018 Nov;36(11):500.e1-500.e9 
 2018Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP 
- 
                                                        Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based AnalysisJournal of Drugs in Dermatology, 2018 
 2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A 
- 
                                                        Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphomaLeukemia and Lymphoma. May 2018;59(5):1133-1142 
 2017Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L 
- 
                                                        Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community settingMedical Oncology. Aug 10 2017;34(9):160 
 2017Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS 
- 
                                                        Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line AndClinical Genitourinary Cancer. 2017 Jun 19. pii: S1558-7673(17)30170-2 
 2017Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS 
- 
                                                        Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practiceSpringerPlus, 2016 03; 5: 395. e-pub ahead of print 2016/04/06 
 2016Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B 
- 
                                                        Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancerBreast Cancer Research and Treatment, 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25 
 2016Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B 
- 
                                                    June 14, 2024
- 
                                                    October 23, 2023
- 
                                                    July 19, 2022
